A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

NCT00665223 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: ACR16
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.